Gagilapur FDA warning letter resolution timeline uncertain
Management could not provide a timeline for FDA reinspection or final resolution, which may delay new product launches from the site.
high · analyst_questionGranules India Limited — Q3 FY26
Granules India delivered a strong Q3 FY26 with consolidated revenue of ₹1,388 crore (+22% YoY) and EBITDA of ₹308 crore (+34% YoY), with margins expanding 196 bps YoY to 22.2%.
bullish
high
✓ Verified against BSE filing
Risk Intelligence
Material risks this quarter
Concise cards keep the risk register scannable while preserving evidence-level context in the underlying quarter data.
Risks
Peptide CDMO quarterly volatility may persist
Despite expected Q4 improvement, management acknowledged quarter-to-quarter variation is inherent to the CDMO business, posing risk to sustained profitability.
medium · management_commentaryParacetamol price erosion despite volume recovery
While inventory levels have eased and volumes are building, management noted price erosion in paracetamol, which could pressure margins.
medium · management_commentaryTentative approval for amphetamine product may take a year for final approval
The generic Adderall approval is tentative due to IP issues; final approval may take a year, delaying potential revenue contribution.
medium · analyst_question